povorcitinib   Click here for help

GtoPdb Ligand ID: 11881

Synonyms: compound 7 [US20210238168A1] | Povofortay®
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: The chemical structure for povorcitinib was revealed in WHO proposed INN list 126 (Jan 2022), in which it was described as a Janus kinase inhibitor and anti-inflammatory agent. It is one of the examples claimed in Incyte's JAK inhibitor patent US20210238168A1 [1], which indicates selectivity for JAK1. At that time information on Incyte's pipeline page suggested that povorcitinib may be the INN for their oral JAK1 inhibitor clinical lead INCB54707, and this INN-to-code name was formally confirmed in 2026 [3].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 102.63
Molecular weight 507.18
XLogP 4.79
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES N#CCC1(CN(C1)c1cc(F)c(cc1F)C(=O)N[C@H](C(F)(F)F)C)n1ncc(c1)c1c(C)n[nH]c1C
Isomeric SMILES C(#N)CC1(CN(C1)c1cc(c(C(=O)N[C@H](C(F)(F)F)C)cc1F)F)n1ncc(c1)c1c(n[nH]c1C)C
InChI InChI=1S/C23H22F5N7O/c1-12-20(13(2)33-32-12)15-8-30-35(9-15)22(4-5-29)10-34(11-22)19-7-17(24)16(6-18(19)25)21(36)31-14(3)23(26,27)28/h6-9,14H,4,10-11H2,1-3H3,(H,31,36)(H,32,33)/t14-/m0/s1
InChI Key MSGYSFWCPOBHEV-AWEZNQCLSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Li Y-L, Zhuo J, Qian D-Q, Mei S, Cao G, Pan Y, Li Q, Jia Z. (2021)
Bipyrazole derivatives as jak inhibitors.
Patent number: US20210238168A1. Assignee: Incyte Corp. Priority date: 17/05/2013. Publication date: 05/08/2021.
2. Porter ML, Martorell A, Sayed CJ, Bechara FG, Lev-Tov H, Hsiao JL, Frew JW, Reguiaï Z, Gooderham MJ, Goldfarb N et al.. (2026)
Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials.
Nat Med, 32 (8): 3071-3081. [PMID:42493571]
3. Zhuo J, Li YL, Qian DQ, Burns DM, Mei S, Rafalski M, Xu M, Cao G, Pan Y, Jia Z et al.. (2026)
Discovery of the Orally Bioavailable Isoform Selective Janus Kinase 1 (JAK1) Compound Povorcitinib (INCB054707) for the Treatment of Inflammatory and Autoimmune Diseases.
J Med Chem, 69 (11): 12830-12852. [PMID:42202255]